A real-world comparison of commercial-use axicabtagene ciloleucel and lisocabtagene maraleucel in large B-cell lymphoma
Andrew Looka(Dana-Farber Cancer Institute), Caron A. Jacobson(Dana-Farber Cancer Institute), Christopher G. Sakellis(Dana-Farber Cancer Institute), Caitlyn Duffy(Harvard University), Erin M. Parry(Broad Institute), Philippe Armand(Harvard University), Anna Saucier(Dana-Farber Cancer Institute), Reid W. Merryman(Harvard University), Eric D. Jacobsen(Dana-Farber Cancer Institute), David Qualls(Memorial Sloan Kettering Cancer Center), Ann S. LaCasce(Otsuka (Japan)), Jennifer L. Crombie(Dana-Farber Cancer Institute), Austin I. Kim(Dana-Farber Cancer Institute), David C. Fisher(Dana-Farber Cancer Institute), Robert Redd(Harvard University)
Cited by 30
Related Papers
PD-1 Blockade with Nivolumab in Relapsed or Refractory Hodgkin's Lymphoma
|New England Journal of Medicine|2014|3.5k
The International Consensus Classification of Mature Lymphoid Neoplasms: a report from the Clinical Advisory Committee
|Blood|2022|1.5k
Navitoclax, a targeted high-affinity inhibitor of BCL-2, in lymphoid malignancies: a phase 1 dose-escalation study of safety, pharmacokinetics, pharmacodynamics, and antitumour activity
|The Lancet Oncology|2010|852
Ipilimumab for Patients with Relapse after Allogeneic Transplantation
|New England Journal of Medicine|2016|595